Benzinga | Nov 18, 2021 07:01AM EST

Mizuho Maintains Buy on Biohaven Pharma Hldgs, Raises Price Target to $144

Mizuho analyst Vamil Divan maintains Biohaven Pharma Hldgs (NYSE:BHVN) with a Buy and raises the price target from $135 to $144.